

blood[®]



ASH Abstracts
2020

Reprinted from:

2020 ASH Annual Meeting Abstracts ***Blood 2020***

Selected abstract

Abstract 131

**Idecabtagene Vicleucel (ide-cel, bb2121),
a BCMA-Directed CAR T Cell Therapy, in Patients
with Relapsed and Refractory Multiple Myeloma:
Updated Results from Phase 1 CRB-401 Study**

Yi Lin et al.

62nd ASH Annual Meeting and Exposition
December 5-8, 2020

© 2020

THE AMERICAN
SOCIETY OF
HEMATOLOGY

Abstract 131

Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study

Yi Lin, MD, PhD¹, Noopur S. Raje, MD², Jesus G. Berdeja, MD³, David S. Siegel, MD⁴, Sundar Jagannath, MD⁵, Deepu Madduri, MD^{6*}, Michaela Liedtke, MD⁶, Jacalyn Rosenblatt, MD⁷, Marcela V. Maus, MD, PhD², Monica Massaro, MPH^{8*}, Fabio Petrocca, MD^{9*}, Andrea Caia, MS^{10*}, Zhihong Yang, PhD^{10*}, Timothy B. Campbell, MD, PhD^{10*}, Kristen Hege, MD¹⁰, Nikhil C. Munshi, MD¹¹ and James N. Kochenderfer, MD¹²

¹Mayo Clinic, Rochester, MN

²Massachusetts General Hospital Cancer Center, Boston, MA

³Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN

⁴Hackensack University Medical Center, Hackensack, NJ

⁵Mount Sinai Medical Center, New York, NY

⁶Stanford University Medical Center, Stanford, CA

⁷Beth Israel Deaconess Medical Center, Boston, MA

⁸bluebird bio, Inc., Cambridge, MA

⁹bluebird bio, Cambridge, MA

¹⁰Bristol Myers Squibb, Princeton, NJ

¹¹Dana-Farber Cancer Institute, Boston, MA

¹²Surgery Branch, National Cancer Institute/National Institutes of Health, Bethesda, MD

*signifies non-member of ASH

Background: Ide-cel, a BCMA-directed CAR T cell therapy, showed tolerability and promising efficacy in patients with relapsed and/or refractory multiple myeloma (RRMM) in the first-in-human phase 1 CRB-401 study (Raje et al. *N Engl J Med.* 2019;380:1726) and the pivotal phase 2 KarMMa study (Munshi et al. *J Clin Oncol.* 2020;38[suppl, abstr]:8503). Ide-cel demonstrated a favorable benefit-risk profile with an overall response rate (ORR) of 85%, a complete response (CR) rate of 45%, and a median progression-free survival (PFS) of 11.8 months in the first 33 patients treated in CRB-401. Reported here are updated safety and efficacy results for 62 patients who received ide-cel in the ongoing CRB-401 study.

Methods: CRB-401 (NCT02658929) is a 2-part, phase 1 dose-escalation and -expansion study. The expansion phase enrolled patients who had received ≥ 3 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, and were refractory to their last line of therapy. Eligibility criteria for the dose-escalation phase were described previously (Raje et al. *N Engl J Med.* 2019;380:1726). After lymphodepletion with fludarabine (30 mg/m²/day) and cyclophosphamide (300 mg/m²/day) for 3 days followed by 2 days of rest, patients received ide-cel at target doses of 50, 150, 450, or 800 $\times 10^6$ CAR+ T cells in the dose-escalation phase and 150 to 450 $\times 10^6$ CAR+ T cells in the dose-expansion phase. The primary endpoint was safety. Secondary endpoints included tumor response according to the International Myeloma Working Group criteria. Exploratory endpoints included PFS, overall survival (OS), and minimal residual disease (MRD).

Results: As of January 14, 2020, 21 patients had received ide-cel in the dose-escalation phase, and 41 patients received ide-cel in the dose-expansion phase. The median age was 61 years, and 44% of patients had high tumor burden ($\geq 50\%$ bone marrow CD138+ plasma cells). Of the 62 patients, 45% received >6 prior regimens, 90% were daratumumab-exposed, and 77% were daratumumab-refractory. As of the cutoff date, 13 patients were ongoing, and 49 patients had discontinued the study. Reasons for study discontinuation were progressive disease (58%), withdrawal by patients (10%), and death (10%). Based on safety and efficacy in the dose-escalation phase, target dose levels of 150 to 450 $\times 10^6$ CAR+ T cells were selected for the dose-expansion phase. The most frequent adverse events (AEs) were neutropenia (92%), cytokine release syndrome (CRS; 76%), anemia (76%), and thrombocytopenia (74%). The most frequent grade 3/4 AEs were neutropenia (89%), leukopenia (61%), anemia (57%), and thrombocytopenia (57%). Most CRS events were grade 1 or 2 (**Table**). Four patients (7%) had grade 3 CRS; there were no grade >3 CRS events. The incidence of CRS generally increased with target dose level. Neurologic toxicity (NT; clustered term) occurred in 27 patients (44%) and was primarily grade 1/2 with 1 patient having grade 3 and 1 patient having grade 4 NT. Among all 62 patients in the dose-escalation and -expansion phases, the ORR was 76%, including 24 patients (39%) with a CR or better and 40 patients (65%) with a very good partial response or better. The median duration of response was 10.3 months. Of 37 responders evaluable for MRD, 30 were MRD negative ($\leq 10^{-4}$ nucleated cells) at 1 or more time point, and 7 responders were MRD positive. With a median

follow-up of 14.7 months for all patients in the dose-escalation and dose-expansion phases, median PFS was 8.8 months and median OS was 34.2 months. Overall, a dose-dependent effect was observed on responses and survival outcomes, with greater efficacy reported at $\geq 150 \times 10^6$ CAR+ T cells (**Table**).

Conclusions: Ide-cel demonstrated deep and durable responses in heavily-pretreated RRMM patients. Efficacy and safety reflect prior reports and support a favorable clinical benefit-risk profile for ide-cel at target dose levels $\geq 150 \times 10^6$ CAR+ T cells.

Target Dose, $\times 10^6$ CAR+ T cells	50 (n=3)	150 (n=18)	450 ^a (n=38)	800 (n=3)	Total (N=62)
Safety^b					
CRS overall, n (%)	2 (67)	7 (39)	35 (92)	3 (100)	47 (76)
Grade ≥ 3 , n (%)	0	0	3 (8)	1 (33)	4 (6)
NT overall, ^c n (%)	0	5 (28)	20 (53)	2 (67)	27 (44)
Grade ≥ 3 , n (%)	0	0	2 (5)	0	2 (3)
Efficacy					
ORR, n (%)	1 (33)	9 (50)	34 (89)	3 (100)	47 (76)
CR rate, ^d n (%)	0	7 (39)	14 (37)	3 (100)	24 (39)
\geq VGPR rate, n (%)	0	7 (39)	30 (79)	3 (100)	40 (65)
Median DOR (95% CI), ^{e,f} mo	1.9 (NE–NE)	13.7 (2.9–39.6)	10.0 (6.3–14.8)	12.9 (10.9–NE)	10.3 (7.7–13.7)
Median PFS (95% CI), ^e mo	2.1 (1.1–2.9)	4.5 (2.0–12.0)	9.0 (7.2–12.2)	13.9 (11.9–NE)	8.8 (5.9–11.9)
Median OS (95% CI), ^e mo	6.0 (5.1–9.3)	NE (10.8–NE)	34.2 (23.2–NE)	21.2 (19.2–NE)	34.2 (19.2–NE)

Data cutoff: January 14, 2020. CR, complete response; CRS, cytokine release syndrome; DOR, duration of response; NA, not applicable; NE, not estimable; NT, neurologic toxicity; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; VGPR, very good partial response.

^aOne patient who received 205×10^6 CAR+ T cells and 1 who received 305×10^6 are included under the 450×10^6 target dose.

^bAdverse events occurring after ide-cel infusion.

^cNT includes preferred terms from focused Medical Dictionary for Regulatory Activities version 22.0: neurotoxicity, confusional state, insomnia, tremor, gait disturbance, somnolence, delirium, disturbance in attention, lethargy, aphasia, bradyphrenia, brain edema, cognitive disorder, depressed level of consciousness, dysarthria, dysgraphia, hallucination, memory impairment, nystagmus, postural tremor, and sleep disorder. All symptoms of CRS are included.

^dDefined as the rate of CR or stringent CR.

^eKaplan-Meier estimate.

^fDuration among responders with partial response or better.

Disclosures:

Lin: Novartis: Consultancy; Janssen: Consultancy, Research Funding; Vineti: Consultancy; Sorrento: Consultancy, Membership on an entity's Board of Directors or advisory committees; Gamida Cells: Consultancy; Takeda: Research Funding; Merck: Research Funding; Legend BioTech: Consultancy; Juno: Consultancy; Celgene: Consultancy, Research Funding; Bluebird Bio: Consultancy, Research Funding; Kite, a Gilead Company: Consultancy, Research Funding. **Raje:** Caribou: Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy; Bluebird, Bio: Consultancy, Research Funding; Takeda: Consultancy; Immuneel: Membership on an entity's Board of Directors or advisory committees; Janssen: Consultancy; Karyopharm: Consultancy; Celgene: Consultancy; Astrazeneca: Consultancy; Amgen: Consultancy. **Berdeja:** Novartis: Research Funding; Lilly: Research Funding; CURIS: Research Funding; Prothena: Consultancy; Celgene: Consultancy, Research Funding; Servier: Consultancy; Genentech, Inc.: Research Funding; EMD Sorono: Research Funding; Cellularity: Research Funding; BMS: Consultancy, Research Funding; Bioclinica: Consultancy; Bluebird: Research Funding; Acetylon: Research Funding; Amgen: Consultancy, Research Funding; Abbvie: Research Funding; Vivolux: Research Funding; Poseida: Research Funding; CRISPR Therapeutics: Consultancy, Research Funding; Teva: Research Funding; Legend: Consultancy; Kite Pharma: Consultancy; Glenmark: Research Funding; Karyopharm: Consultancy; Janssen: Consultancy, Research Funding; Constellation: Research Funding; Kesios: Research Funding; Takeda: Consultancy, Research Funding. **Siegel:** Karyopharma: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Speakers Bureau; BMS: Consultancy, Honoraria, Speakers Bureau; Janssen: Consultancy, Honoraria, Speakers Bureau; Merck: Consultancy, Honoraria, Speakers Bureau; Amgen: Consultancy, Honoraria, Speakers Bureau; Celutairy: Consultancy. **Jagannath:** Janssen: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Legend Biotech: Consultancy, Honoraria; Karyopharm: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Takeda: Consultancy, Honoraria. **Madduri:** Legend: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; Celgene: Consultancy, Honoraria; Kinevant: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau; Foundation Medicine: Consultancy, Honoraria; AbbVie: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; GSK: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Speaking Engagement, Speakers Bureau. **Liedtke:** Pfizer: Honoraria; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Janssen: Membership on an entity's Board of Directors or advisory committees; GSK: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Caelum: Membership on an entity's Board of Directors or advisory committees; Adaptive: Membership on an entity's Board of Directors or advisory committees. **Rosenblatt:** Celgene: Research Funding. **Maus:** Novartis: Consultancy, Research Funding; arcellx: Consultancy, Research Funding; kite: Consultancy, Research Funding; century therapeutics: Current equity holder in private company; tcr2: Consultancy, Current equity holder in publicly-traded company. **Massaro:** bluebird, bio: Current Employment, Current equity holder in publicly-traded company. **Petrocca:** bluebird, bio: Current Employment, Current equity holder in publicly-traded company. **Caia:** Celgene a BMS company: Current Employment, Current equity holder in publicly-traded company. **Yang:** Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company; Celgene: Ended employment in the past 24 months. **Campbell:** BMS: Current Employment, Current equity holder in publicly-traded company. **Hege:** Bristol Myers Squibb: Current Employment, Current equity holder in publicly-traded company, Other: TRAVEL, ACCOMMODATIONS, EXPENSES (paid by any for-profit health care company), Patents & Royalties: numerous, Research Funding; Celgene (acquired by Bristol Myers Squibb): Ended employment in the past 24 months; Mersana Therapeutics: Current equity holder in publicly-traded company, Membership on an entity's Board of Directors or advisory committees; Arcus Biosciences (Former Board of Directors): Divested equity in a private or publicly-traded company in the past 24 months. **Munshi:** BMS: Consultancy; OncoPep: Consultancy, Current equity holder in private company, Membership on an entity's Board of Directors or advisory committees, Patents & Royalties; AbbVie: Consultancy; Karyopharm: Consultancy; Takeda: Consultancy; Adaptive: Consultancy; Janssen: Consultancy; C4: Current equity holder in private company; Amgen: Consultancy; Legend: Consultancy. **Kochenderfer:** Celgene: Patents & Royalties, Research Funding; bluebird, bio: Patents & Royalties; Kite, a Gilead company: Patents & Royalties, Research Funding.

All rights reserved. © 2020 by The American Society of Hematology
Cover image: © Sebastian Schreiter / Springer Medizin Verlag GmbH

Reprinted with permission from the American Society of Hematology, which does not endorse any particular uses of this document. The copyright in the contents and material in this publication is owned by American Society of Hematology as the Publisher. Although great care has been taken in compiling the content of this publication, neither Springer Healthcare, the Publisher or their agents are responsible or liable in any way for the currency of the information, for any errors, omissions or inaccuracies in the original or in translation, or for any consequences arising therefrom. Approved product information should be reviewed before use.



Springer Healthcare Ibérica S.L.

Rosario Pino, 14 - 4ª Planta. 28020 Madrid. Spain

Tel.: +34 91 555 40 62. Fax: +34 91 555 76 89

E-mail: Miguel.Quesada@springer.com

www.springerhealthcare.com

www.springernature.com

Part of the Springer Nature group